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1. Introduction
Glycogen phosphorylase (EC 2.4.1.1) inhibitors (GPIs) have been
considered as possible means for therapeutic intervention in type 2
diabetes and some other diseased states (e.g., early cardiac and car-
diovascular disease in non-diabetics, cardiac arrhythmias, ischae-
mic injuries, and tumour growth) as rationalized in the recent
review literature.1–5 Among several compound classes4,6 glucose
derivatives are one of the most intensively investigated inhibi-
tors.5,7 The quoted review articles5,7 provide the reader with a
detailed description of the structure–activity relationships (SAR)
of glucose analogue GPIs, therefore, only those features are sum-
marized hereinafter which form the direct basis of our compound
design. N-Acyl-b-D-glucopyranosylamines8 (Chart 1, I: e.g. for
R = 2-naphthyl Ki measured against rabbit muscle GPb (RMGPb)9
was 10–13 lM,8,10) N-aryl-N0-b-D-glucopyranosyl ureas4,11 II
(R = 2-naphthyl: Ki (RMGPb) 5.2 lM), as well as N-acyl-N0-b-D-glu-
copyranosyl urea derivatives4,12 III (R = 2-naphthyl: Ki (RMGPb)
0.35 lM) have been shown to inhibit the enzyme in the low micro-
molar range. As a part of a programme to replace the NHCO moiety
0008-6215/$ - see front matter  2013 Published by Elsevier Ltd.
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l-[C-(b-D-glucopyranosyl)formaldehyde]semicarbazone was prepared in th
ed b-D-glucopyranosyl cyanide and 4-phenylsemicarbazide in the presenc
f O-perbenzoylated C-(b-D-glucopyranosyl)formaldehyde semicarbazon
g 4-acyl-[C-(b-D-glucopyranosyl)formaldehyde]semicarbazones. The reactio
-D-glucopyranosyl)formaldehyde semicarbazone with the correspondin
at SciVerse ScienceDirect
te Research
elsevier .com/locate /carresin O-perbenzoylated C-(b-D-glucopyranosyl)formaldehyde thiosemicarba-
ivative. Acylation of O-perbenzoylated C-(b-D-glucopyranosyl)formaldehyde
d the corresponding 4-acyl-2-acylamino-5-(b-D-glucopyranosyl)-D2-1,3,4-
transformations of these precursors gave O-protected 2-(b-D-glucopyrano-
,3,4-oxa- and -thiadiazoles. The O-benzoyl protecting groups were removed
sesteriﬁcation conditions. The C-glucopyranosyl heterocyclic compounds
bit muscle glycogen phosphorylase b, however, the semicarbazones showed
nhibitor was 4-phenyl-[C-(b-D-glucopyranosyl)formaldehyde]semicarbazone
 2013 Published by Elsevier Ltd.
of the above compounds by non-classical bioisosteric heterocyclic
linkers, among others we have carried out the synthesis of
compounds IA.13 Enzymatic tests as well as crystallographic stud-
ies revealed high similarity of the amide (see Ki of I above) and the
1,2,3-triazole type (for IA R = 2-naphthyl: Ki (RMGPb) 16 lM)
70inhibitors both in binding strength and structural features of the
enzyme–inhibitor complexes.10 Applying the isomeric oxadiazoles
B, D, and E as linkers resulted in inhibitors of varying efﬁciency,
whereby the 3-aryl-5-b-D-glucopyranosyl-1,2,4-oxadiazole (IE
type) derivatives proved to be the most potent compounds (for
the best inhibitor where R = 2-naphthyl the Ki (RMGPb) was
2.4 lM).14,15
Herein we report on the synthesis and enzymatic test of
compounds of type II and III with 1,3,4-oxadiazole B and 1,3,4-
thiadiazole C as linkers representing bioisosteric replacements of
80NHCO moieties of N-substituted-N0-b-D-glucopyranosyl ureas.
These studies contribute to an extension of SAR related to interac-
tions of inhibitors in the b-channel of the enzyme which can
accommodate aglycons of the glucose analogue compounds and
is lined with amino acid side chains of mixed character.16
2. Results and discussion
For the formation of the heterocyclic parts of the target com-
pounds oxidative ring closure of (thio)semicarbazones (similar to
13), http://dx.doi.org/10.1016/j.carres.2013.03.009
that applied for the syntheses of IB15) was envisaged as the key
step. To this end, the protected C-(b-D-glucopyranosyl)formalde-
90 hyde semicarbazone 2 was prepared by a reaction of NH2C
(@O)NHNH2 with O-perbenzoylated b-D-glucopyranosyl cyanide17
1 in the presence of Raney Ni and NaH2PO2 at 40 C (Scheme 1)
as described earlier.18 O-Perbenzoylated 4-phenyl-[C-(b-D-gluco-
pyranosyl)formaldehyde]semicarbazone 3 was obtained in a
similar way using PhNHC(@O)NHNH2 as the trapping agent.
Debenzoylation was performed by the Zemplén protocol to result
in moderate yields of semicarbazones 6 and 7.
In order to get thiosemicarbazones 4 and 5, acid catalysed
transimination of 2 was carried out because the direct transforma-
100tionofb-D-glucopyranosyl cyanide1 into thiosemicarbazones failed.
Thus, semicarbazone 2 was reacted with NH2C(@S)NHNH2 or
PhNHC(@S)NHNH2 in glacial AcOH at 70 C to give the correspond-
ing thiosemicarbazones 4 and 5, respectively. Removal of the ben-
zoyl protecting groups in 4 and 5was carried out by LiOH in MeOH
to give compounds 8 and 9, respectively, in satisfactory yields.
To obtain precursors for compounds IIIB semicarbazone 2 was
treated by acid chlorides in CH2Cl2 in the presence of Et3N to give
O-perbenzoylated 4-acyl-[C-(b-D-glucopyranosyl)formaldehyde]
semicarbazones 12–15 in satisfactory yields (Scheme 2). Under
110these conditions no reaction took place with thiosemicarbazone
3. Acylation of 3 in dry pyridine at 80 C resulted in the formation
of 4-acyl-2-acylamino-5-(b-D-glucopyranosyl)-D2-1,3,4-thiadiazo-
lines 16–19 as inseparable mixtures of two diastereoisomers in
good yields. This observation is in accord with the literature
experiences.19
Ring closing reactions of the precursors under oxidative
conditions were studied next. Semicarbazone 3 was reacted with
Pb (OAc)4 in glacial AcOH at 70 C to furnish O-perbenzoylated
2-phenylamino-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)-1,
CN
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S3,4-ox adiazole 10 (Scheme 2). Trials to use other oxidizing agent
such as FeCl3 or PIDA failed, 3 was recovered in these reaction
Deprotection of 10 was achieved by the Zemplén method to giv
11 in an excellent yield. Thiosemicarbazone 4 resisted severa
oxidation reagents (PIDA, Pb(OAc)4, FeCl3, Br2, and K3Fe(CN)6
Semicarbazones 12–15 were reacted with PIDA in CH2Cl2 at rt t
get O-perbenzoylated 2-acylamino-5-(b-D-glucopyranosyl)-1,3,4
oxadiazoles 20–23 in good yields (Scheme 2). Thiadiazolines 16
19 were oxidized in a similar way to result in 1,3,4-thiadiazoles
24–27. Debenzoylations were performed by the Zemplén protoco
to give good and excellent yields of 1,3,4-oxadiazoles 28–31 an
1,3,4-thiadiazoles 32–35.
The deprotected compounds were tested for their inhibitio
potency against rabbit muscle glycogen phosphorylase b (RMGPb
according to the protocol described earlier.20 The results are sum
marized in Table 1 also showing the inhibitory efﬁciency of som
relevant reference compounds.
Replacement of the NHCO moiety in compound type II (entry 1
by a 1,3,4-oxadiazole ring (11) resulted in a loss of inhibition.
similar observation was made with compounds type III whereb
on changing the NHCO group of the acylurea derivatives (entr
2) to either 1,3,4-oxadiazole (entry 3, 28–31) or 1,3,4-thiadiazol
(entry 4, 32–35) the efﬁciency was lost. These ﬁndings resembl
those obtained with compounds type IB in Chart 1 where 1,3,4
oxadiazole replacements in N-acyl-glucopyranosylamines resulte
in practically inactive compounds.15 It follows from these result
that the 1,3,4-oxadiazole and 1,3,4-thiadiazole moieties canno
contribute to favourable interactions in the b-channel of RMGPb
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a No inhibition at a tested concentration of 625 lM.
b Calculated from the IC50 value by using a web-based tool.22Please cite this article in press as: Sz}ocs, B.; et al. Carbohydr. Res. (20Interestingly, semicarbazones 6 and 7 (entry 6) and thiosem
carbazones 8 and 9 (entry 7), the ‘open chain’ precursors of th
target compounds of this work, showed week to moderate inhib
tion. Semicarbazones 6 and 7 are better inhibitors than the thio
semicarbazone counterparts 8 and 9. Phenyl derivatives 7 and
are more efﬁcient than the unsubstituted compounds 6 and 8
respectively, and this is in agreement with the general trend t
show stronger inhibition by those compounds which have a lar
ge(r) aromatic part in the aglycon.4 A comparison of 7 (actuall
the best inhibitor in this study) to the biuret type inhibitor (entr
5) indicates no signiﬁcant difference in the inhibition constant
This may reveal that interactions of the whole NHCO linker moiet
or its carbonyl group has probably less signiﬁcance in binding t
the enzyme than those of the ‘second’ NHCO unit.
3. Conclusion
The reductive transformation of D-glycopyranosyl cyanides i
the presence of acylhydrazines was extended to the preparatio
of new anhydro-aldose semicarbazone and thiosemicarbazon
derivatives. Acylation of semicarbazones yielded the expecte
4-acyl semicarbazones, while under similar conditions thiosem
carbazones gave O-peracylated 4-acyl-2-acylamino-5-(b-D-gluco
pyranosyl)-D2-1,3,4-thiadiazolines. Oxidation of the aforeme
tioned precursors resulted in protected 2-(b-D-glucopyranosyl)-5
(substituted-amino)-1,3,4-oxa- and thiadiazoles, respectivel
After O-deprotection enzyme kinetic measurements showed th
1,3,4-oxa- and -thiadiazoles to be inactive against rabbit muscl
ivatives and the new compounds (Ki [lM])
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Plcogen phosphorylase b. However, the precursor ‘open chain’ 4-
enyl semicarbazone proved to be a low micromolar GPI, equipo-
nt with a biuret derivative of similar chain length between the
gar and the aromatic part of the molecule. Replacement of the
ygen by a sulfur atom caused the loss of activity. This latter ﬁnd-
g may indicate a difference in contribution to the binding of the
o NHCO unites of N-acyl-N0-glucopyranosyl urea type inhibitors
glycogen phosphorylase.
Experimental
. General methods
Melting points were measured in open capillary tubes or on a
ﬂer hot-stage and are uncorrected. Optical rotations were
termined with a Perkin–Elmer 241 polarimeter at room temper-
ure. NMR spectra were recorded with Bruker 360 (360/90 MHz
r 1H/13C) or Bruker 400 (400/100 MHz for 1H/13C) spectrometers.
emical shifts are referenced to TMS as the internal reference
), or to the residual solvent signals (13C). Microanalyses
re performed on an Elementar vario Micro cube. ESI-MS were
corded with a Thermo Scientiﬁc LTQ XL instrument. TLC was
rformed on DC-Alurolle Kieselgel 60 F254 (Merck). TLC plates
re visualized under UV light, and by gentle heating with a
mmercially available heat gun without any charring reagent.
r column chromatography Kieselgel 60 (Merck, particle size
.063–0.200 mm) was applied. Organic solutions were dried over
hydrous MgSO4, and concentrated under diminished pressure at
–50 C (water bath).
. 4-Phenyl-[C-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)
rmaldehyde]semicarbazone (3)
Raney Ni (3.53 g, from an aqueous suspension, Merck) was
ded at rt to a vigorously stirred solution of pyridine (14 mL),
O (9 mL), and AcOH (9 mL). Then, NaH2PO2 (1.76 g, 20.0 mmol),
,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl) cyanide17 (1, 1.50 g,
8 mmol), and PhNHC(@O)NHNH2 (0.75 g, 4.96 mmol) were
ded to the mixture. The reaction mixture was stirred and heated
40 C. When the reaction was complete (TLC, 1:2 EtOAc/hexane)
e insoluble materials were ﬁltered off with suction, and washed
th EtOAc (3  15 mL). The organic layer of the ﬁltrate was sepa-
ted, washed with 10% HCl (2  15 mL), saturated NaHCO3 solu-
n (3  20 mL), H2O (2  15 mL), dried, and concentrated under
duced pressure. Traces of pyridine were removed by repeated
-evaporations with toluene. The crude product was puriﬁed by
lumn chromatography (2:3 EtOAc/hexane) to yield 1.17 g (64%)
3 as a white amorphous product. [a]D = +33 (c 0.52, CHCl3); Rf:
4 (1:1 EtOAc/hexane); 1H NMR (CDCl3, 360 MHz) d (ppm)
.36 (1H, s, NH), 8.20 (1H, s, NH), 8.05–7.02 (26H, m, Ar, CH@N),
8, 6.03, 5.77 (3H, 3 pt, J = 9.2, 9.5 Hz in each, H-2, H-3, H-4), 4.67
H, dd, J6a,6b = 12.7 Hz, H-6a), 4.53 (1H, dd, J1,CH@N = 4.1 Hz,
2 = 9.1 Hz, H-1), 4.40 (1H, dd, H-6b), 4.25 (1H, ddd,
6a = 3.0 Hz, J5,6b = 4.5 Hz, J4,5 = 9.9 Hz, H-5). 13C NMR (CDCl3,
0 MHz) d (ppm) 166.0, 165.8, 165.0 (CO), 153.7 (NHCONH),
8.0 (CH@N), 136.5–119.4 (Ar), 76.3, 76.2, 74.3, 69.3 (C-1 to
5), 63.0 (C-6). Anal. Calcd for C42H35N3O10 (741.74): C, 68.01,
4.76; N, 5.67. Found: C, 69.00; H, 4.83; N, 5.62.
. C-(2,3,4,6-Tetra-O-benzoyl-b-D-glucopyranosyl)
rmaldehyde thiosemicarbazone (4)
C-(2,3,4,6-Tetra-O-benzoyl-b-D-glucopyranosyl)formaldehyde
micarbazone18 (2, 1.50 g, 2.25 mmol) was dissolved in glacial
OH (65 mL) and then NH2C(@S)NHNH2 (0.83 g, 9.05 mmol)ease cite this article in press as: Sz}ocs, B.; et al. Carbohydr. Res. (2013),s added. The mixture was stirred and heated at 70 C. The reac-
n was monitored by TLC (1:1 EtOAc/hexane). When the reaction
s complete, the reaction mixture was diluted with H2O
00 mL), and extracted with EtOAc (4  20 mL), and washed with
HCO3 (3  25 mL), and H2O (1  20 mL). The organic phase was
ied (MgSO4), and evaporated under reduced pressure. The crude
oduct was puriﬁed by column chromatography (1:1 EtOAc/hex-
e) to give 1.30 g (85%) of 4 as a yellow amorphous product 4.
]D = +11 (c 0.35, CHCl3); Rf: 0.33 (1:2 EtOAc/hexane); 1H NMR
DCl3, 360 MHz) d (ppm) 9.94 (1H, s, NH), 8.07–7.10 (21H, m,
, CH@N), 6.34 (1H, s, J = 2.4 Hz, NH), 5.98, 5.87, 5.71 (3H, 3 pt,
9.5, 9.8 Hz in each, H-2, H-3, H-4), 4.66 (1H, dd, J6a,6b = 12.5 Hz,
6a), 4.49–4.43 (2H, m, H-1, H-6b), 4.22 (1H, ddd, J5,6a = 2.9 Hz,
6b = 5.0 Hz, J4,5 = 9.9 Hz, H-5). 13C NMR (CDCl3, 360 MHz) d
pm) 179.2 (CS), 166.1, 165.9, 165.8, 165.1 (CO), 139.2 (CH@N),
3.7–128.3 (Ar), 76.9, 76.4, 73.9, 69.6, 69.1 (C-1 to C-5), 62.9
-6). Anal. Calcd for C36H31N3O9S (681.71): C, 63.43, H, 4.58; N,
6; S, 4.70. Found: C, 63.54; H, 4.67; N, 6.09; S, 4.78.
. 4-Phenyl-[C-(2,3,4,6-tetra-O-benzoyl-b-D-
copyranosyl)formaldehyde]thiosemicarbazone (5)
C-(2,3,4,6-Tetra-O-benzoyl-b-D-glucopyranosyl)formaldehyde
micarbazone18 (2, 1.00 g, 1.50 mmol) was dissolved in glacial
OH (43 mL) and then PhNHC(@S)NHNH2 (0.83 g, 9.05 mmol)
s added. The mixture was stirred and heated at 70 C. The reac-
n was monitored by TLC (1:1 EtOAc/hexane). When the reaction
s complete, the reaction mixture was diluted with H2O
50 mL), and extracted with EtOAc (4  15 mL), and washed with
HCO3 (3  20 mL), and H2O (1  15 mL). The organic phase was
ied (MgSO4), and evaporated under reduced pressure. The crude
oduct was puriﬁed by column chromatography (1:1.5 EtOAc/
xane) to yield 1.00 g (87%) of 5 as a yellow amorphous product.
]D = +7 (c 0.33, CHCl3); Rf: 0.55 (1:1 EtOAc/hexane); 1H NMR
DCl3, 360 MHz) d (ppm) 10.74 (1H, s, NH), 9.19 (1H, s, NH),
4–7.18 (26H, m, Ar, CH@N), 6.09–5.99 (2H, m, H-2 and/or H-3
d/or H-4), 5.76 (1H, 1 pt, J = 9.3 Hz, H-2 or H-3 or H-4), 4.66
H, dd, J5,6a = 2.4 Hz, J6a,6b = 12.2 Hz, H-6a), 4.54 (1H, dd, J1,
@N = 4.0 Hz, J1,2 = 9.2 Hz, H-1), 4.49 (1H, dd, J5,6b = 5.3 Hz,
6b), 4.26–4.22 (1H, m, H-5). 13C NMR (CDCl3, 360 MHz) d
pm) 176.0 (CS), 166.0, 165.2, 165.2, 164.9 (CO), 138.1 (CH@N),
7.6–124.5 (Ar), 76.0, 76.1, 74.1, 69.33, 69.1 (C-1 to C-5), 62.8
-6). Anal. Calcd for C42H35N3O9S (757.81): C, 66.57, H, 4.66; N,
4; S, 4.23. Found: C, 66.63; H, 4.72; N, 5.58; S, 4.29.
. 2-Phenylamino-5-(2,3,4,6-tetra-O-benzoyl-b-D-
copyranosyl)-1,3,4-oxadiazole (10)
Semicarbazone 3 (0.20 g, 0.27 mmol) was dissolved in glacial
OH (3 mL). Then Pb(OAc)4 (0.18 g, 0.40 mmol) was added, and
e mixture was stirred and heated at 70 C. The reaction was
onitored by TLC (1:2 EtOAc/hexane). When the reactionwas com-
ete, the reaction mixture was diluted with H2O (15 mL), and ex-
cted with EtOAc (3  6 ml). The organic phase was dried
gSO4), and evaporated under reduced pressure. The crude prod-
t was puriﬁed by column chromatography (1:2 EtOAc/hexane)
yield 90 mg (45%) of 10 as a white amorphous product. [a]D = –
(c 0.21, CHCl3); Rf: 0.41 (1:2 EtOAc/hexane); 1H NMR (CDCl3,
0 MHz) d (ppm) 8.87 (1H, s, NH), 8.02–7.00 (25H, m, Ar), 6.08,
3, 5.83 (3H, 3 pt, J = 9.5, 9.7 Hz in each, H-2, H-3, H-4), 5.13
H, d, J1,2 = 9.9 Hz, H-1), 4.65 (1H, dd, J5,6a = 2.0 Hz, J6a,6b = 12.4 Hz,
6a), 4.51 (1H, dd, J5,6b = 5.2 Hz, H-6b) 4.40–4.30 (1H, m, H-5). 13C
R (CDCl3, 360 MHz) d (ppm) 166.1, 165.7, 165.1, 164.9 (CO),
1.2, 154.8 (C-oxadiazole), 137.4–117.8 (Ar), 76.8, 73.6, 71.9,
.1, 69.1 (C-1 to C-5), 63.0 (C-6). Anal. Calcd for C42H33N3O10
39.73): C, 68.19, H, 4.50; N, 5.68. Found: C, 68.25; H, 4.59; N, 5.61.http://dx.doi.org/10.1016/j.carres.2013.03.009
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27 March 20134.6. General procedure I for the synthesis of O-perbenzoylated
4-acyl-[C-(b-D-glucopyranosyl)formaldehyde]semicarbazones
C-(2,3,4,6-Tetra-O-benzoyl-b-D-glucopyranosyl)formaldehyde
semicarbazone18 (2, 0.10 g, 0.15 mmol) was dissolved in dr
CH2Cl2 (5 mL), and then Et3N (0.063 mL, 0.45 mmol) and RCOC
(0.45 mmol) were added. The mixture was stirred and heated a
40 C. The reaction was monitored by TLC (1:1 EtOAc/hexane
When the reaction was complete, the solvent was evaporated
and the residue was puriﬁed by column chromatography.
4.6.1. 4-Acetyl-[C-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)formaldehyde]semicarbazone (12)
From 2 (0.19 g, 0.29 mmol) and AcCl (62 lL, 0.87 mmol) accord
ing to General procedure I (Section 4.6). Puriﬁed by column chro
matography (1:1.5 EtOAc/hexane) to yield 91 mg (47%) of 12 as
yellow amorphous product. [a]D = +8 (c 0.35, CHCl3); Rf: 0.37 (1:
EtOAc/hexane); 1H NMR (CDCl3, 360 MHz) d (ppm) 9.83 (1H,
NH), 8.10–7.80 (8H, m, Ar), 7.58–7.18 (14H, m, Ar, CH@N, NH
6.00, 5.73, 5.66 (3H, 3 pt, J = 9.6, 9.7 Hz in each, H-2, H-3, H-4
4.65 (1H, dd, J5,6a = 1.8 Hz, J6a,6b = 12.2 Hz, H-6a), 4.52–4.37 (2H
m, H-1, H-6b), 4.28–4.17 (1H, m, H-5), 1.91 (3H, s, CH3). 13C NM
(CDCl3, 360 MHz) d (ppm) 173.8, 166.1, 165.8, 165.3, 165.1, 158.
(CO, NHCO, NHCONH), 140.5 (CH@N), 133.4–128.2 (Ar), 77.7
76.2, 73.7, 70.2, 69.3 (C-1 to C-5), 63.0 (C-6), 19.7 (CH3). Anal. Calc
for C38H33N3O11 (707.68): C, 64.49, H, 4.70; N, 5.94. Found: C
64.59; H, 4.79; N, 5.86.
4.6.2. 4-Benzoyl-[C-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)formaldehyde]semicarbazone (13)
From 2 (0.10 g, 0.15 mmol) and BzCl (53 lL, 0.45 mmol) accord
ing to General procedure I (Section 4.6). Puriﬁed by column chro
matography (1:1.5 EtOAc/hexane) to yield 81 mg (70%) of 13 as
yellow amorphous product. [a]D = –61 (c 0.18, CHCl3); Rf: 0.5
(1:1 EtOAc/hexane); 1H NMR (CD3CN, 360 MHz) d (ppm) 10.2
(1H, br s, NH), 8.06–7.30 (27H, m, Ar, CH@N, NH), 6.06, 5.80, 5.7
(3H, 3 pt, J = 9.5, 9.8 Hz in each, H-2, H-3, H-4), 4.70–4.65 (1H, m
H-5), 4.59 (2H, dd, J5,6a = 2.4 Hz, J6a,6b = 12.5 Hz, H-6a), 4.53 (1H
dd, J5,6b = 4.1 Hz, H-6b), 4.42 (1H, d, J1,2 = 9.1 Hz, H-1). 13C NM
(CD3CN, 360 MHz) d (ppm) 166.7, 166.4, 166.1, 166.0, 164.5 (CO
NHCO, NHCONH), 145.9 (CH@N) 134.5–118.2 (Ar), 78.6, 76.5
75.1, 71.5, 70.0 (C-1 to C-5), 63.7 (C-6). Anal. Calcd fo
C43H35N3O11 (769.75): C, 67.09, H, 4.58; N, 5.46. Found: C, 67.01
H, 4.50; N, 5.55.
4.6.3. 4-(2-Naphthoyl)-[C-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)formaldehyde]semicarbazone (14)
From 2 (0.20 g, 0.30 mmol) and 2-naphthoyl chloride (172 m
0.90 mmol) according to General procedure I (Section 4.6). Puriﬁe
by column chromatography (1:3,5 EtOAc/toluene) to yield 123 m
(50%) of 14 as a yellow amorphous product. [a]D = –134 (c 0.16
CHCl3); Rf: 0.43 (1:3.5 EtOAc/toluene); 1H NMR (CDCl3, 360 MHz
d (ppm) 9.79 (1H, br s, NH), 8.18–7.23 (29H, m, Ar, CH@N, NH
6.06, 5.77, 5.65 (3H, 3 pt, J = 8.7 Hz, 9.3 Hz in each, H-2, H-3, H-4
4.73–4.58 (2H, m, H-1, H-6a), 4.48 (1H, dd, J5,6b = 4.9 H
J6a,6b = 12.1 Hz, H-6b), 4.32–4.19 (1H, m, H-5). 13C NMR (CDCl
360 MHz) d (ppm) 166.1, 165.7, 165.3, 164.3 (CO, NHCO, NHCONH
145.1 (CH@N), 134.8–123.8 (Ar), 78.5, 76.3, 73.6, 70.8, 69.4 (C-1 t
C-5), 63.2 (C-6). Anal. Calcd for C47H37N3O11 (819.81): C, 68.86, H
4.55; N, 5.13. Found: C, 68.97; H, 4.65; N, 5.20.
4.6.4. 4-(4-tert-Butylbenzoyl)-[C-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)formaldehyde]semicarbazone (15)
From 2 (0.10 g, 0.15 mmol) and 4-tert-butylbenzoyl chlorid
(88 lL, 0.45 mmol) according to General procedure I (Sectio
4.6). Puriﬁed by column chromatography (1:2 EtOAc/hexane) to
Please cite this article in press as: Sz}ocs, B.; et al. Carbohydr. Res. (20yield 68 mg (55%) of 15 as a yellow amorphous produc
[a]D = +41 (c 0.52, CHCl3); Rf: 0.27 (1:2 EtOAc/hexane); 1H NM
(CDCl3, 360 MHz) d (ppm) 9.66 (1H, br s, NH), 8.01–7.21 (26H, m
Ar, CH@N, NH), 6.06, 5.77, 5.64 (3H, 3 pt, J = 8.6, 9.3 Hz in each
H-2, H-3, H-4), 4.76–4.56 (2H, m, H-1, H-6a), 4.49 (1H, dd
J5,6b = 4.9 Hz, J6a,6b = 12.1 Hz, H-6b), 4.32–4.18 (1H, m, H-5), 1.2
(9H, s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.0, 165.9
165.6, 165.2 (CO, NHCO, NHCONH), 144.6 (CH@N), 155.4, 133.4
125.2 (Ar), 78.6, 76.2, 73.6, 70.8, 69.3 (C-1 to C-5), 63.2 (C-6
34.7 (CtBu), 30.9 (CH3). Anal. Calcd for C47H43N3O11 (825.86): C
68.35, H, 5.25; N, 5.09. Found: C, 68.44; H, 5.36; N, 5.16.
4.7. General procedure II for the synthesis of 4-acyl-2-
acylamino-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)-D2-
1,3,4-thiadiazolines
C-(2,3,4,6-Tetra-O-benzoyl-b-D-glucopyranosyl)formaldehyde
thiosemicarbazone (4, 0.10 g, 0.14 mmol) was dissolved in dry pyr
idine (5 mL) and then RCOCl (0.44 mmol) was added. The mixtur
was stirred and heated at 80 C. The reaction was monitored by TL
(1:2 EtOAc/hexane). When the reaction was complete, the solven
was evaporated, and the residue was puriﬁed by colum
chromatography.
4.7.1. 2-Acetamido-4-acetyl-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-D2-1,3,4-thiadiazoline (16)
From 4 (0.20 g, 0.28 mmol) and AcCl (60 lL, 0.84 mmol) accord
ing to General procedure II (Section 4.7). Puriﬁed by column chro
matography (1:2 EtOAc/toluene) to yield 170 mg (77%) of 16 as
white amorphous product. [a]D = –178 (c 0.35, CHCl3); Rf: 0.3
(1:2 EtOAc/toluene); ESI-MS (positive mode) m/z: 766.25 [M+H]
Anal. Calcd for C40H35N3O11S (765.78): C, 62.74, H, 4.61; N, 5.49
S, 4.19. Found: C, 62.71; H, 4.65; N, 5.46; S, 4.15.
major isomer: 1H NMR (CDCl3, 360 MHz) d (ppm) 9.43 (1H,
NH), 8.10–7.11 (20H, m, Ar), 6.05–5.96 (2H, m, H-2 or H-3 o
H-4, CH-thiadiazoline), 5.68, 5.56 (2H, 2 pt, J = 9.8 Hz in each
H-2 and/or H-3 and/or H-4), 4.53–4.42 (3H, m, H-6a, H-6b, H-1
4.15–4.08 (1H, m, H-5), 1.99, 1.93 (6H, 2 s, CH3). 13C NMR (CDCl
360 MHz) d (ppm) 169.0, 166.0, 165.6, 165.0 (CO, NHCO), 147.
(Cq-thiadiazoline), 133.6–125.1 (Ar), 76.0, 75.2, 73.5, 69.1, 66.
(C-1 to C-5), 69.1 (CH-thiadiazoline), 62.4 (C-6), 22.6, 21.5 (CH3)
Minor isomer: 1H NMR (CDCl3, 360 MHz) d (ppm) 9.14 (1H,
NH), 5.84, 5.43 (2H, 2 pt, J = 9.5, 9.7 Hz in each, H-2 and/or H-
and/or H-4).
4.7.2. 2-Benzamido-4-benzoyl-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-D2-1,3,4-thiadiazoline (17)
From 4 (0.50 g, 0.74 mmol) and BzCl (258 lL, 2.22 mmo
according to General procedure II (Section 4.7). Puriﬁed by colum
chromatography (1:2 EtOAc/hexane) to yield 400 mg (62%) of 17 a
a yellow amorphous product. [a]D = –295 (c 0.16, CHCl3); Rf: 0.3
(1:2 EtOAc/hexane). ESI-MS (positive mode) m/z: 890.33 [M+H]
Anal. Calcd for C50H39N3O11S (889.92): C, 67.48, H, 4.42; N, 4.72
S, 3.60. Found: C, 67.42; H, 4.45; N, 5.71; S, 3.63.
major isomer: 1H NMR (CDCl3, 400 MHz) d (ppm) 9.26 (1H,
NH) 8.05–7.10 (30H, m, Ar), 6.34 (1H, s, CH-thiadiazoline), 6.0
(1H, pt, J = 9.5 Hz, H-2 or H-3 or H-4), 5.72–5.60 (2H, m, H-2 and
or H-3 and/or H-4), 4.62 (1H, d, J1,2 = 9.7 Hz, H-1), 4.54 (1H, dd
J5,6a = 5.3 Hz, J6a,6b = 12.3 Hz, H-6a), 4.48 (1H, dd, J5,6b = 1.9 H
H-6b), 4.17–4.11 (1H, m, H-5). 13C NMR (CDCl3, 400 MHz)
(ppm) 166.6, 166.2, 165.7, 165.7, 165.1, 165.0 (CO, NHCO), 148.
(Cq-thiadiazoline) 133.7–127.3 (Ar), 76.5, 75.9, 73.7, 69.2, 67.
(C-1 to C-5), 69.1 (CH-thiadiazoline), 62.6 (C-6).
Minor isomer: 1H NMR (CDCl3, 400 MHz) d (ppm) 9.10 (1H,
NH), 6.63 (1H, s, CH-thiadiazoline), 6.09, 5.90 (2H, 2 pt, J = 9.5 H
in each, H-2 and/or H-3 and/or H-4), 4.72 (1H, d, J1,2 = 9.1 Hz,
13), http://dx.doi.org/10.1016/j.carres.2013.03.009
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Pl1), 4.67 (1H, dd, J5,6a = 2.3 Hz, J6a,6b = 12.4 Hz, H-6a), 4.41 (1H, dd,
6b = 4.9 Hz, H-6b), 4.26–4.20 (1H, m, H-5). 13C NMR (CDCl3,
0 MHz) d (ppm) 76.1, 74.8, 68.6 (C-1 to C-5), 60.3 (C-6).
.3. 2-(2-Naphthamido)-4-(2-naphtoyl)-5-(2,3,4,6-tetra-O-
nzoyl-b-D-glucopyranosyl)-D2-1,3,4-thiadiazoline (18)
From 4 (0.50 g, 0.74 mmol) and 2-naphthoyl chloride (423 mg,
2 mmol) according to General procedure II (Section 4.7). Puri-
d by column chromatography (1:2 EtOAc/hexane) to yield
0 mg (62%) of 18 as a yellow amorphous product. [a]D = –318
0.16, CHCl3); Rf: 0.43 (1:8 EtOAc/toluene). ESI-MS (positive
ode) m/z: 990.33 [M+H]+. Anal. Calcd for C58H43N3O11S
89.26): C, 70.36, H, 4.38; N, 4.24; S, 3.24. Found: C, 70.32; H,
6; N, 4.21; S, 3.27.
Major isomer: 1H NMR (CDCl3, 400 MHz) d (ppm) 9.30 (1H, s,
) 8.36–6.84 (34H, m, Ar), 6.36 (1H, d, CH-thiadiazoline), 5.96
H, pt, J = 9.5 Hz, H-2 or H-3 or H-4), 5.70–5.61 (2H, m, H-2 and/
H-3 and/or H-4), 4.60 (1H, dd, J1,CH = 1.4 Hz, J1,2 = 9.9 Hz, H-1),
2 (1H, dd, J6a,6b = 12.2 Hz, H-6a,), 4.46 (1H, dd, H-6b), 3.97
H, ddd, J5,6b = 2.7 Hz, J5,6a = 4.9 Hz, J4,5 = 9.7 Hz, H-5). 13C NMR
DCl3, 400 MHz) d (ppm) 169.7, 166.5, 166.3, 165.8, 165.7, 165.0
O, NHCO), 148.1 (Cq-thiadiazoline), 135.3–123.5 (Ar), 76.4,
.8, 73.7, 69.1, 68.0 (C-1 to C-5), 69.1 (CH-thiadiazoline), 62.5
-6).
Minor isomer: 1H NMR (CDCl3, 400 MHz) d (ppm) 6.68 (1H, d,
-thiadiazoline), 6.13, 5.89 (2H, 2 pt, J = 9.5 Hz in each, H-2
d/or H-3 and/or H-4), 4.76 (1H, dd, J1,CH = 2.5 Hz, J1,2 = 9.8 Hz,
1), 4.65 (1H, dd, J6a,6b = 12.3 Hz, H-6a), 4.19 (1H, ddd,
6a = 2.8 Hz, J5,6b = 4.6 Hz, J4,5 = 9.6 Hz, H-5). 13C NMR (CDCl3,
0 MHz) d (ppm) 167.3, 166.2, 165.4, 164.9 (CO, NHCO), 148.7
q-thiadiazoline), 76.1, 75.4, 74.8, 68.5, 67.8 (C-1 to C-5), 63.0
-6).
.4. 2-(4-tert-Butylbenzamido)-4-(4-tert-butylbenzoyl)-5-
,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)-D2-1,3,4-
iadiazoline (19)
From 4 (0.15 g, 0.22 mmol) and 4-tert-butylbenzoyl chloride
29 lL, 0.66 mmol) according to General procedure II (Section
). Puriﬁed by column chromatography (1:4 EtOAc/hexane) to
ld 83 mg (38%) of 19 as a yellow amorphous product. [a]D = –
8 (c 0.18, CHCl3); Rf: 0.48 (1:2 EtOAc/hexane); 1H NMR (CDCl3,
0 MHz) d (ppm) 8.71 (1H, s, NH), 8.01–7.14 (28H, m, Ar), 6.36
H, d, J = 1.4 Hz, CH-thiadiazoline), 6.01, 5.65, 5.64 (3H, 3 pt,
9.5 Hz in each, H-2, H-3, H-4), 4.64–4.55 (2H, m, H-6a, H-1),
2 (1H, dd, J6a,6b = 12.0 Hz, H-6b), 4.14 (1H, ddd, J5,6b = 2.0 Hz,
6a = 5.7 Hz, J4,5 = 9.5 Hz, H-5), 1.36 (9H, br s, CH3), 1.31 (9H, s,
3). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.4, 166.3, 165.8,
5.8, 165.2, 164.7 (CO, NHCO), 156.9, 154.3 (Cq-phenyl), 145.9
q-thiadiazoline), 133.7–124.7 (Ar), 76.6, 76.0, 73.8, 69.3, 67.8,
-1 to C-5), 69.1 (CH-thiadiazoline), 62.8 (C-6), 35.2, 34.9 (Cq),
.2, 31.1 (CH3). ESI-MS (positive mode) m/z: 1002.33 [M+H]+.
al. Calcd for C58H55N3O11S (1002.14): C, 69.51, H, 5.53; N,
9; S, 3.20. Found: C, 69.54; H, 5.56; N, 4.16; S, 3.25.
. General procedure III for the synthesis of 2-acylamino-5-
,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)-1,3,4-oxadiazoles
d -thiadiazoles
A 4-acyl-[C-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)form-
ehyde]semicarbazone (12–15, 0.03 mmol) or a 2-acylamino-
acyl-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)-1,3,4-thi-
iazoline (16–19, 0.03 mmol) was dissolved in CH2Cl2 (1 mL).
en PIDA (1.1 equiv) was added, and the mixture was stirred
room temperature. The reaction was monitored by TLC (1:1
OAc/hexane). When the reaction was complete, the solventease cite this article in press as: Sz}ocs, B.; et al. Carbohydr. Res. (2013),s evaporated and the residue was puriﬁed by column
romatography.
.1. 2-Acetamido-5-(2,3,4,6-tetra-O-benzoyl-b-D-
copyranosyl)-1,3,4-oxadiazole (20)
From 12 (0.16 g, 0.23 mmol) according to General procedure III
ection 4.8). Puriﬁed by column chromatography (1:3 EtOAc/hex-
e) to yield 81 mg (50%) of 20 as a white amorphous product.
]D = –2 (c 0.25, CHCl3); Rf: 0.38 (1:3 EtOAc/toluene); 1H NMR
DCl3, 360 MHz) d (ppm) 8.03–7.22 (21H, m, Ar, NH), 6.08, 5.86,
4 (3H, 3 pt, J = 9.7 Hz in each H-2, H-3, H-4), 5.18 (1H d,
2 = 9.8 Hz, H-1), 4.71–4.60 (1H, dd, J5,6a < 1 Hz, H-6a), 4.52 (1H,
, J5,6b = 4.3 Hz, J6a,6b = 12.1 Hz, H-6b), 4.40–4.30 (1H, m, H-5),
3 (1H, s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.0,
5.6, 165.2, 165.0, 164.8, 160.9 (CO, NHCO, C-oxadiazole),
3.5–128.3 (Ar), 76.9, 73.4, 71.8, 70.3, 68.9 (C-1 to C-5), 62.9 (C-
, 11.0 (CH3). Anal. Calcd for C38H31N3O11 (705.67): C, 64.68, H,
3; N, 5.95. Found: C, 64.60; H, 4.51; N, 5.86.
.2. 2-Benzamido-5-(2,3,4,6-tetra-O-benzoyl-b-D-
copyranosyl)-1,3,4-oxadiazole (21)
From 13 (0.084 g, 0.11 mmol) according to General procedure III
ection 4.8). Puriﬁed by column chromatography (1:3 EtOAc/hex-
e) to yield 70 mg (57%) of 21 as a white amorphous product.
]D = –205 (c 0.4, CHCl3); Rf: 0.68 (1:1 EtOAc/hexane); 1H NMR
DCl3, 360 MHz) d (ppm) 8.06–7.26 (26H, m, Ar, NH), 6.11, 6.02,
8 (3H, 3 pt, J = 9.5, 9.8 Hz in each H-2, H-3, H-4), 5.28 (1H d,
2 = 9.8 Hz, H-1), 4.71 (1H, dd, J6a,6b = 12.4 Hz, H-6a), 4.54 (1H,
, H-6b) 4.39 (1H, ddd, J5,6a = 2.4 Hz, J5,6b = 5.2 Hz, J4,5 = 9.4 Hz,
5). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.0, 165.9, 165.6,
5.1, 164.8, 160.9 (CO, NHCO, C-oxadiazole), 133.5–123.3 (Ar),
.0, 73.5, 71.8, 70.2, 69.0 (C-1 to C-5), 62.9 (C-6). Anal. Calcd for
3H33N3O11 (767.74): C, 67.27, H, 4.33; N, 5.47. Found: C, 67.35;
4.42; N, 5.40.
.3. 2-(2-Naphthamido)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
copyranosyl)-1,3,4-oxadiazole (22)
From 14 (0.28 g, 0.34 mmol) according to General procedure III
ection 4.8). Puriﬁed by column chromatography (1:6 EtOAc/tolu-
e) to yield 192 mg (69%) of 22 as a yellow amorphous product.
]D = –121 (c 0.16, CHCl3); Rf: 0.58 (1:3.5 EtOAc-toluene); 1H
R (CDCl3, 360 MHz) d (ppm) 8.52 (1H, s, NH), 8.11–7.10 (27H,
, Ar), 6.18, 6.11, 5.95 (3H, 3 pt, J = 9.7 Hz in each, H-2, H-3,
4), 5.27 (1H, d, J1,2 = 9.5 Hz, H-1), 4.70 (1H, dd, J6a,6b = 12.4 Hz,
6a), 4.54 (1H, dd, H-6b) 4.39 (1H, ddd, J5,6a = 2.7 Hz,
6b = 4.3 Hz, J4,5 = 9.5 Hz, H-5). 13C NMR (CDCl3, 360 MHz) d
pm) 166.0, 165.9, 165.6, 164.8, 161.1 (CO, NHCO, C-oxadiazole),
4.7–120.5 (Ar), 77.0, 73.6, 71.9, 70.3, 69.1 (C-1 to C-5), 63.0
-6). Anal. Calcd for C47H35N3O11 (817.79): C, 69.03, H, 4.31; N,
4. Found: C, 69.11; H, 4.41; N, 5.05.
.4. 2-(4-tert-Butylbenzamido)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
copyranosyl)-1,3,4-oxadiazole (23)
From 15 (0.09 g, 0.11 mmol) according to General procedure III
ection 4.8). Puriﬁed by column chromatography (1:3 EtOAc/hex-
e) to yield 80 mg (60%) of 23 as a colourless amorphous product.
]D = –82 (c 1.50, CHCl3); Rf: 0.29 (1:3 EtOAc/hexane); 1H NMR
DCl3, 360 MHz) d (ppm) 8.05–7.20 (25H, m, Ar, NH), 6.11, 6.02,
8 (3H, 3 pt, J = 9.5, 9.7 Hz in each, H-2, H-3, H-4), 5.28 (1H, d,
2 = 9.7 Hz, H-1), 4.70 (1H, dd, J6a,6b = 12.4 Hz, H-6a), 4.54 (1H,
, H-6b), 4.40 (1H, ddd, J5,6a = 2.3 Hz, J5,6b = 5.3 Hz, J4,5 = 9.7 Hz,
5), 1.34 (9H, s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.0,
5.9, 165.6, 165.1, 164.8, 161.1 (CO, NHCO, C-oxadiazole), 155.6,
3.5–120.5 (Ar), 77.0, 73.6, 71.8, 70.2, 69.1 (C-1 to C-5), 63.0
-6), 35.0 (Cq-tBu), 31.0 (CH3). Anal. Calcd for C47H41N3O11http://dx.doi.org/10.1016/j.carres.2013.03.009
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27 March 2013(823.84): C, 68.52, H, 5.02; N, 5.10. Found: C, 68.61; H, 5.11; N
5.18.
4.8.5. 2-Acetamido-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-thiadiazole (24)
From 16 (0.17 g, 0.22 mmol) according to General procedure I
(Section 4.8). Puriﬁed by column chromatography (1:2 EtOAc/tolu
ene) to yield 106 mg (67%) of 24 as a white amorphous produc
[a]D = –81 (c 0.25, CHCl3); Rf: 0.42 (1:2 EtOAc/toluene); 1H NM
(CDCl3, 360 MHz) d (ppm) 8.09–7.13 (21H, m, Ar, NH), 6.09, 5.81
5.74 (3H, 3 pt, J = 9.6, 9.8 Hz in each, H-2, H-3, H-4), 5.25 (1H, d
J1,2 = 9.6 Hz, H-1), 4.70 (1H, dd, J6a,6b = 12.3 Hz, H-6a), 4.53 (1H
dd, H-6b), 4.36 (1H, ddd, J5,6a = 3.0 Hz, J5,6b = 4.8 Hz, J4,5 = 9.5 H
H-5), 1.82 (3H, s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 168.8
166.1, 165.7, 165.1, 164.7 (CO, NHCO, C-thiadiazole), 133.5–128.
(Ar), 76.9, 76.0, 73.5, 71.7, 69.2 (C-1 to C-5), 62.9 (C-6). ESI-MS (po
sitive mode) m/z: 722.33 [M+H]+. Anal. Calcd for C38H31N3O10
(721.76): C, 63.24, H, 4.33; N, 5.82; S,4.44. Found: C, 63.21; H
4.35; N, 5.84; S, 4.41.
4.8.6. 2-Benzamido-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-thiadiazole (25)
From 17 (0.09 g, 0.10 mmol) according to General procedure I
(Section 4.8). Puriﬁed by column chromatography (1:3 EtOAc/hex
ane) to yield 54 mg (68%) of 25 as a white amorphous produc
[a]D = –111 (c 0.20, CHCl3); Rf: 0.21 (1:2 EtOAc/hexane); 1H NM
(CDCl3, 360 MHz) d (ppm) 8.20–7.26 (26H, m, Ar, NH), 6.12, 5.86
5.77 (3H, 3 pt, J = 9.5, 9.8 Hz in each, H-2, H-3, H-4), 5.32 (1H, d
J1,2 = 9.7 Hz, H-1), 4.70 (1H, dd, J6a,6b = 12.4 Hz, H-6a), 4.55 (1H
dd, H-6b) 4.40 (1H, ddd, J5,6a = 2.7 Hz, J5,6b = 5.0 Hz, J4,5 = 9.7 H
H-5). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.2, 165.7, 165.1
165.0, 164.9, 162.5, 161.1 (CO, NHCO, C-thiadiazole), 133.3–128.
(Ar), 77.0, 76.3, 73.6, 72.2, 69.2, (C-1 to C-5), 63.1 (C-6). Anal. Calc
for C43H33N3O10S (783.8): C, 65.89, H, 4.24; N, 5.36; S,4.09. Found
C, 65.94; H, 4.35; N, 5.28; S, 4.01.
4.8.7. 2-(2-Naphthamido)-5-(2,3,4,6-tetra-O-benzoyl-b-D-
glucopyranosyl)-1,3,4-thiadiazole (26)
From 18 (0.20 g, 0.20 mmol) according to General procedure I
(Section 4.8). Puriﬁed by column chromatography (1:6 EtOAc/tolu
ene) to yield 100 mg (59%) of 26 as a yellow amorphous produc
[a]D = 205 (c 0.16, CHCl3); Rf: 0.39 (1:6 EtOAc/toluene); 1H NM
(CDCl3, 360 MHz) d (ppm) 8.71 (s, 1H, NH), 8.12–7.11 (27H, m
Ar), 6.15, 5.91, 5.80 (3H, 3pt, J = 9.6 Hz in each, H-2, H-3, H-4
5.35 (1H, d, J1,2 = 9.7 Hz, H-1), 4.70 (1H, dd, Jia,6b = 12.3 Hz, H-6a
4.57 (1H, dd, H-6b), 4.41 (1H, ddd, J5,6a = 2.0 Hz, J5,6b = 4.9 H
J4,5 = 9.4 Hz, H-5). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.1
165.7, 165.2, 165.1, 165.0, 162.5, 160.9 (CO, NHCO, C-thiadiazole
135.5–124.2 (Ar), 76.9, 76.3, 73.6, 72.3, 69.3 (C-1 to C-5), 63.1 (C
6). ESI-MS (positive mode) m/z: 834.33 [M+H]+. Anal. Calcd fo
C47H35N3O10S (833.86): C, 67.70, H, 4.23; N, 5.04; S, 3.85. Found
C, 67.81; H, 4.15; N, 5.12; S, 3.76.
4.8.8. 2-(4-tert-Butylbenzamido)-5-(2,3,4,6-tetra-O-benzoyl-b-D
glucopyranosyl)-1,3,4-thiadiazole (27)
From 19 (0.17 g, 0.17 mmol) according to General procedure I
(Section 4.8). Puriﬁed by column chromatography (1:3 EtOAc/hex
ane) to yield 120 mg (84%) of 27 as a white amorphous produc
[a]D = –179 (c 0.20, CHCl3); Rf: 0.20 (1:3 EtOAc/hexane); 1H NM
(CDCl3, 360 MHz) d (ppm) 8.05–7.22 (25H, m, Ar, NH), 6.12, 5.86
5.80 (3H, 3 pt, J = 9.5, 9.7 Hz in each, H-2, H-3, H-4), 5.31 (1H, d
J1,2 = 9.6 Hz, H-1), 4.68 (1H, dd, J5,6a < 1 Hz, J6a,6b = 12.2 Hz, H-6a
4.54 (1H, dd, J5,6b = 5.0 Hz, H-6b), 4.43–4.35 (1H, m, H-5), 1.3
(9H, s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 166.1, 165.8
165.2, 165.0, 164.8, 161.8, 160.9 (CO, NHCO, C-thiadiazole
156.9, 133.5–125.8 (Ar), 76.9, 76.3, 73.7, 72.2, 69.4 (C-1 to C-5),
Please cite this article in press as: Sz}ocs, B.; et al. Carbohydr. Res. (2063.2 (C-6), 31.9 (Cq-tBu), 31.1 (CH3). ESI-MS (positive mode) m/z
840.42 [M+H]+. Anal. Calcd for C47H41N3O10S (839.91): C, 67.21
H, 4.92; N, 5.00; S, 3.82. Found: C, 67.31; H, 4.83; N, 5.09; S, 3.91
4.9. Preparation for the test compounds
4.9.1. General procedure IV for the Zemplén debenzoylation
An O-perbenzoylated compound (100 mg) was dissolved in dr
MeOH (1 mL) and a solution of NaOMe (1 M in MeOH) was adde
to the solution in a catalytic amount. The reaction mixture wa
kept at rt. When the reaction was complete (TLC, 7:3 CHCl3/MeOH
the solution was neutralized with a cation exchange resin Amber
lyst 15 (H+ form). The resin was ﬁltered off with suction, the ﬁltrat
was evaporated under reduced pressure. The crude product wa
puriﬁed by column chromatography.
4.9.2. General procedure V for the removal of O-benzoyl
protecting groups
An O-perbenzoylated compound (100 mg) was dissolved in dr
MeOH (14 mL) and LiOH (16 equiv) was added. The reaction mix
ture was stirred at 0 C. When the reaction was complete (TLC, 7:
CHCl3/MeOH) the solution was neutralized with a cation exchang
resin Amberlyst 15 (H+ form). After ﬁltration and removal of the so
vent, the residue was puriﬁed by column chromatography.
4.9.3. C-(b-D-Glucopyranosyl)formaldehyde semicarbazone (6)
From 2 (0.17 g, 0.26 mmol) according to General procedure I
(Section 4.9.1). Puriﬁed by column chromatography (8:5 CHCl
methanol) to yield 40 mg (63%) of 6 as a white amorphous produc
[a]D = +32 (c 0.30, DMSO); Rf: 0.17 (2:1 CHCl3/methanol); 1H NM
(MeOD, 360 MHz) d (ppm) 7.19 (1H, s, CH@N), 3.88–3.72 (2H, m
H-1, H-2 or H-3 or H-4), 3.70–3.52 (1H, m, H-6a), 3.50–3.22 (4H
m, H-2 and/or H-3 and/or H-4, H-5, H-6b). 13C NMR (MeOD
360 MHz) d (ppm) 160.1 (NHCONH), 143.2 (CH@N), 81.8, 80.2
79.4, 73.4, 71.4 (C-1 to C-5), 62.7 (C-6). Anal. Calcd fo
C84H15N3O6 (249.22): C, 38.55, H, 6.07; N, 16.86. Found: C, 38.63
H, 6.12; N, 16.93.
4.9.4. 4-Phenyl-[C-(b-D-glucopyranosyl)formaldehyde]
semicarbazone (7)
From 3 (0.20 g, 0.27 mmol) according to General procedure I
(Section 4.9.1). Puriﬁed by column chromatography (4:1 CHCl
methanol) to yield 42 mg (48%) of 7 as a white amorphous produc
[a]D = +52 (c 0.43, DMSO); Rf: 0.23 (4:1 CHCl3/methanol); 1H NM
(MeOD, 360 MHz) d (ppm) 7.46 (2H, d, J = 7.9 Hz, Ar), 7.30–7.1
(3H, m, Ar, CH@N), 7.01 (1H, t, J = 7.3 Hz, Ar), 3.91–3.79 (2H, m
H-1, H-2 or H-3 or H-4), 3.65 (1H, dd, J5,6a = 4.5 Hz, J6a,6b = 11.4 H
H-6a), 3.42–3.21 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b
13C NMR (MeOD, 360 MHz) d (ppm) 155.9 (NHCONH), 143.
(CH@N), 139.7, 129.8, 124.5, 121.3 (Ar), 82.0, 80.2, 79.5, 73.5
71.5 (C-1/C-5), 62.8 (C-6). Anal. Calcd for C14H19N3O6 (325.32): C
51.69, H, 5.89; N, 12.92. Found: C, 51.79; H, 5.98; N, 12.85.
4.9.5. C-(b-D-glucopyranosyl)formaldehyde thiosemicarbazone
(8)
From 4 (0.16 g, 0.24 mmol) according to General procedure
(Section 4.9.2). Puriﬁed by column chromatography (3:1 CHCl
methanol) to yield 60 mg (95%) of 8 as a white amorphous produc
[a]D = +6 (c 2.00, DMSO); Rf: 0.24 (3:1 CHCl3/methanol); 1H NM
(MeOD, 360 MHz) d (ppm) 7.39 (1H, s, CH@N), 3.92–3.81 (2H, m
H-1, H-2 or H-3 or H-4), 3.68 (1H, dd, J5,6a = 3.1 Hz, J6a,6b = 10.9 H
H-6a), 3.52–3.32 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b
13C NMR (MeOD, 360 MHz) d (ppm) 180.0 (NHCSNH), 145.
(CH@N), 81.7, 79.8, 79.0, 73.2, 71.4 (C-1/C-5), 62.7 (C-6). Ana
Calcd for C8H15N3O5S (265.29): C, 36.22, H, 5.70; N, 15.84;66012.09. Found: C, 36.12; H, 5.81; N, 15.92; S, 12.17.
13), http://dx.doi.org/10.1016/j.carres.2013.03.009
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Pl.6. 4-Phenyl-[C-(b-D-glucopyranosyl)formaldehyde]
iosemicarbazone (9)
From 5 (0.20 g, 0.26 mmol) according to General procedure V
ection 4.9.2). Puriﬁed by column chromatography (7:1 CHCl3/
ethanol) to yield 70 mg (77%) of 9 as a yellow amorphous
oduct. [a]D = +33 (c 0.13, MeOH); Rf: 0.40 (3:1 CHCl3/metha-
l); 1H NMR (MeOD, 360 MHz) d (ppm) 7.61 (2H, d,
7.8 Hz, Ar), 7.42–7.30 (3H, m, Ar, CH@N), 7.21 (1H, t,
7.4 Hz, Ar), 3.97–3.82 (2H, m, H-1, H-2 or H-3 or H-4), 3.71
H, dd, J5,6a = 4.8 Hz, J6a,6b = 11.8 Hz, H-6a), 3.48–3.33 (4H, m,
2 and/or H-3 and/or H-4, H-5, H-6b). 13C NMR (MeOD,
0 MHz) d (ppm) 178.3 (NHCSNH), 144.7 (CH@N), 140.1,
9.4, 126.8, 126.2 (Ar), 82.0, 80.1, 79.5, 73.4, 71.5 (C-1/C-5),
.8 (C-6). Anal. Calcd for C13H19N3O5S (341.38): C, 49.26, H,
1; N, 12.31; S, 9.39. Found: C, 49.19; H, 5.70; N, 12.39; S,
9.
.7. 2-Phenylamino-5-(b-D-glucopyranosyl)-1,3,4-oxadiazole
1)
From 10 (0.16 g, 0.22 mmol) according to General procedure
(Section 4.9.1). Puriﬁed by column chromatography (7:1
Cl3/methanol) to yield 68 mg (97%) of 11 as a white amor-
ous product. [a]D = +14 (c 0.21, DMSO); Rf: 0.24 (7:1 CHCl3/
ethanol); 1H NMR (MeOD, 360 MHz) d (ppm) 7.49 (2H, d,
8.0 Hz, Ar), 7.33 (2H, t, J = 7.6 Hz, Ar), 7.03 (1H, t, J = 7.3 Hz,
), 4.44 (1H, d, J1,2 = 9.9 Hz, H-1), 3.93–3.85 (1H, m, H-6a),
7–3.65 (2H, m, H-2 or H-3 or H-4, H-6b), 3.55–3.37 (3H, m,
2 and/or H-3 and/or H-4, H-5). 13C NMR (MeOD, 360 MHz) d
pm) 162.4, 159.2 (C-oxadiazole), 139.6, 130.2, 123.8, 118.8
r), 82.6, 79.1, 74.6, 73.2, 71.3 (C-1/C-5), 62.8 (C-6). Anal. Calcd
r C14H17N3O6 (323.30): C, 52.01, H, 5.30; N, 13.00. Found: C,
.11; H, 5.39; N, 13.11.
.8. 2-Acetamido-5-(b-D-glucopyranosyl)-1,3,4-oxadiazole
8)
From 20 (0.18 g, 0.62 mmol) according to General procedure IV
ection 4.9.1). Puriﬁed by column chromatography (5:1 CHCl3/
ethanol) to yield 30 mg (41%) of 28 as a white amorphous prod-
t. [a]D = +38 (c 0.15, H2O); Rf: 0.28 (3:1 CHCl3/methanol); 1H
R (D2O+MeOD, 360 MHz) d (ppm) 4.69 (1H, d, J1,2 = 9.9 Hz, H-
, 3.91 (1H, dd, J5,6a = 1.4 Hz, J6a,6b = 12.1 Hz, H-6a), 3.82–3.70
H, m, H-2 or H-3 or H-4, H-6b), 3.66–3.57 (2H, m, H-2 or H-3
H-4, H-5), 3.52 (1H, pt, J = 9.2 Hz, H-2 or H-3 or H-4), 2.57
H, s, CH3). 13C NMR (D2O+MeOD, 360 MHz) d (ppm) 166.6
HCO, C-oxadiazole), 163.8 (C-oxadiazole), 80.4, 76.6, 72.3, 71.5,
.2 (C-1 to C-5), 62.7 (C-6), 10.0 (CH3). Anal. Calcd for
0H15N3O7 (289.24): C, 41.52, H, 5.23; N, 14.53. Found: C, 41.59;
5.29; N, 14.62.
.9. 2-Benzamido-5-(b-D-glucopyranosyl)-1,3,4-oxadiazole
0)
From 21 (0.15 g, 0.43 mmol) according to General procedure
(Section 4.9.1). Puriﬁed by column chromatography (8:1
Cl3/methanol) to yield 60 mg (87%) of 29 as a white amor-
ous product. [a]D = +11 (c 0.13, DMSO); Rf: 0.26 (3:1 CHCl3/
ethanol); 1H NMR (MeOD, 360 MHz) d (ppm) 8.07 (2H, d,
7.2 Hz, Ar), 7.65–7.50 (3H, m, Ar), 4.66 (1H d, J1,2 = 9.8 Hz,
1), 3.93 (1H, dd, J5,6a = 1.4 Hz, J6a,6b = 12.1 Hz, H-6a), 3.85 (1H,
, J = 9.0 Hz, H-2 or H-3 or H-4), 3.74 (1H, dd, J5,6b = 5.2 Hz,
6b) 3.60–3.43 (3H, m, H-2 and/or H-3 and/or H-4, H-5,). 13C
R (MeOD, 360 MHz) d (ppm) 166.8 (NHCO, C-oxadiazole),
5.6 (C-oxadiazole), 133.4, 130.4, 128.0, 124.6 (Ar), 82.8, 79.0,
.6, 73.4, 71.2 (C-1 to C-5), 62.7 (C-6). Anal. Calcd for
5H17N3O7 (351.31): C, 51.28, H, 4.88; N, 11.96. Found: C,
.20; H, 4.93; N, 12.06.
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adiazole (30)
From 22 (0.16 g, 0.40 mmol) according to General procedure
(Section 4.9.1). Puriﬁed by column chromatography (8:1
Cl3/methanol) to yield 73 mg (93%) of 30 as a white amor-
ous product. [a]D = +13 (c 0.10, DMSO); Rf: 0.13 (8:1 CHCl3/
ethanol); 1H NMR (DMSO-d6, 360 MHz) d (ppm) 7.81 (1H, br
Ar), 7.35–7.10 (4H, m, Ar), 6.82 (2H, br s, Ar), 3.87 (1H, d,
2 = 9.6 Hz, H-1), 3.15–3.02 (2H, m, H-2 or H-3 or H-4, H-6a,),
7–2.87 (1H, m, H-6b), 2.80–2.64 (3H, m, H-2 and/or H-3
d/or H-4, H-5,). 13C NMR (DMSO-d6, 360 MHz) d (ppm) 164.8
HCO, C-oxadiazole), 164.2 (C-oxadiazole), 134.4–120.5 (Ar),
.9, 77.3, 72.9, 71.8, 69.9 (C-1/C-5), 61.0 (C-6). Anal. Calcd for
9H19N3O7 (401.37): C, 56.86, H, 4.77; N, 10.47. Found: C,
.79; H, 4.88; N, 10.38.
.11. 2-(4-tert-Butylbenzamido)-5-(b-D-glucopyranosyl)-1,3,4-
adiazole (31)
From 23 (0.15 g, 0.37 mmol) according to General procedure IV
ection 4.9.1). Puriﬁed by column chromatography (7:1 CHCl3/
ethanol) to yield 56 mg (76%) of 31 as a white amorphous prod-
t. [a]D = +13 (c 0.29, DMSO); Rf: 0.30 (7:1 CHCl3/methanol); 1H
R (MeOD, 360 MHz) d (ppm) 7.99 (2H, d, J = 8.2 Hz, Ar), 7.62
H, d, J = 8.2 Hz, Ar), 4.66 (1H, d, J1,2 = 9.8 Hz, H-1), 3.92 (1H, m,
6a), 3.84 (1H, pt, J = 9.1 Hz, H-2 or H-3 or H-4), 3.72 (1H, dd,
6b = 4.6 Hz, J6a,6b = 12.0 Hz, H-6b), 3.62–3.42 (3H, m, H-2 and/or
3 and/or H-4, H-5), 1.37 (9H, s, CH3). 13C NMR (MeOD,
0 MHz) d (ppm) 167.0 (NHCO, C-oxadiazole), 165.4 (C-oxadiaz-
), 157.3, 127.9, 127.4, 121.8 (Ar), 82.9, 79.1, 74.6, 73.4, 71.3
-1 to C-5), 62.8 (C-6), 36.0 (Cq-tBu), 31.5 (CH3). Anal. Calcd for
9H25N3O7 (407.42): C, 56.01, H, 6.18; N, 10.31. Found: C, 56.12;
6.27; N, 10.21.
.12. 2-Acetamido-5-(b-D-glucopyranosyl)-1,3,4-thiadiazole
2)
From 24 (0.18 g, 0.59 mmol) according to General procedure IV
ection 4.9.1). Puriﬁed by column chromatography (8:1 CHCl3/
ethanol) to yield 70 mg (92%) of 32 as a white amorphous prod-
t. [a]D = +25 (c 0.27, DMSO); Rf: 0.12 (8:1 CHCl3/methanol); 1H760R (DMSO-d6, 360 MHz) d (ppm) 4.48 (1H, d, J1,2 = 9.0 Hz, H-1),
9 (1H, dd, J5,6a = 4.8 Hz, J6a,6b = 11.6 Hz, H-6a), 3.47–3.27 (4H,
, H-2, H-3, H-4, H-6b), 3.22–3.18 (1H, m, H-5), 2.19 (3H, s,
3). 13C NMR (DMSO-d6, 360 MHz) d (ppm) 168.5 (NHCO),
2.8, 158.9 (C-thiadiazole), 81.5, 77.6, 76.7, 74.5, 69.9 (C-1 to C-
, 61.1 (C-6), 22.3 (CH3). Anal. Calcd for C10H15N3O6S (305.31):
39.34, H, 4.95; N, 13.76; S, 10.50. Found: C, 39.25; H, 4.86; N,
.65; S, 10.59.
.13. 2-Benzamido-5-(b-D-glucopyranosyl)-1,3,4-thiadiazole
3)
770From 25 (0.11 g, 0.30 mmol) according to General procedure IV
ection 4.9.1). Puriﬁed by column chromatography (8:1 CHCl3/
ethanol) to yield 35 mg (68%) of 33 as a white amorphous prod-
t. [a]D = +9 (c 0.20, DMSO); Rf: 0.13 (8:1 CHCl3/methanol); 1H
R (DMSO-d6, 360 MHz) d (ppm) 8.09 (2H, d, J = 7.5 Hz, Ar),
6 (1H, pt, J = 7.2 Hz, Ar), 7.56 (2H, pt, J = 7.5 Hz, Ar), 4.54 (1H,
J1,2 = 8.7 Hz, H-1), 3.76–3.66 (1H, m, H-6a), 3.45 (1H, dd,
6b = 6.0 Hz, J6a,6b = 11.9 Hz, H-6b), 3.40–3.29 (3H, m, H-2 and/or
3 and/or H-4, H-5), 3.20 (1H, t, J = 8.7 Hz, H-2 or H-3 or H-4).
NMR (DMSO-d6, 360 MHz) d (ppm) 165.5 (NHCO), 163.4,
7800.2 (C thiadiazole), 133.2, 131.6, 128.9, 128.5 (Ar), 81.7, 77.6,
.9, 74.6, 70.0 (C-1 to C-5), 61.2 (C-6). ESI-MS (positive mode)
z: 368.08 [M+H]+. Anal. Calcd for C15H17N3O6S (367.38): C,
.04, H, 4.66; N, 11.44; S, 8.73. Found: C, 49.13; H, 4.75; N,
.53; S, 8.62.
http://dx.doi.org/10.1016/j.carres.2013.03.009
4.9.14. 2-(2-Naphthamido)-5-(b-D-glucopyranosyl)-1,3,4-
thiadiazole (34)
From 26 (0.14 g, 0.34 mmol) according to General procedure IV
(Section 4.9.1). Puriﬁed by column chromatography (7:1 CHCl3/
methanol) to yield 40 mg (57%) of 34 as a white amorphous prod-
790 uct. [a]D = +10 (c 1.10, DMSO); Rf: 0.32 (7:1 CHCl3/methanol); 1H
NMR (DMSO-d6, 360 MHz) d (ppm) 8.81 (1H, br s, Ar), 8.15–8.00
(4H, m, Ar), 7.72–7.60 (2H, m, Ar), 4.55 (1H, d, J1,2 = 8.9 Hz, H-1),
3.76–3.68 (1H, m, H-6a), 3.40–3.30 (4H, m, H-2 and/or H-3 and/
or H-4, H-5, H-6b), 3.21 (1H, pt, J = 8.9 Hz, H-2 or H-3 or H-4).
13C NMR (DMSO-d6, 360 MHz) d (ppm) 165.5 (NHCO), 163.2,
160.0 (C-thiadiazole), 134.9–122.8 (Ar), 81.6, 77.6, 76.8, 74.5,
69.9 (C-1 to C-5), 61.1 (C-6). Anal. Calcd for C19H19N3O6S
(417.44): C, 54.67, H, 4.59; N, 10.07; S, 7.68. Found: C, 54.56; H,
4.68; N, 10.01; S, 7.78.
800 4.9.15. 2-(4-tert-Butylbenzamido)-5-(b-D-glucopyranosyl)-1,3,4-
thiadiazole (35)
From 27 (0.18 g, 0.43 mmol) according to General procedure IV
(Section 4.9.1). Puriﬁed by column chromatography (7:1 CHCl3/
methanol) to yield 60 mg (66%) of 35 as a white amorphous prod-
uct. [a]D = +9 (c 1.00, DMSO); Rf: 0.36 (7:1 CHCl3/methanol); 1H
NMR (DMSO-d6, 360 MHz) d (ppm) 8.07 (2H, d, J = 8.2 Hz, Ar),
7.59 (2H, d, J = 8.2 Hz, Ar), 4.55 (1H, d, J1,2 = 8.6 Hz, H-1), 3.78–
3.70 (1H, m, H-6a), 3.48 (1H, dd, J5,6b = 5.9 Hz, J6a,6b = 11.8 Hz, H-
6b), 3.41–3.30 (3H, m, H-2 and/or H-3 and/or H-4, H-5), 3.22
810 (1H, pt, J = 8.7 Hz, H-2 or H-3 or H-4), 1.33 (9H, s, CH3). 13C NMR
(DMSO-d6, 360 MHz) d (ppm) 165.1 (NHCO), 163.3, 160.0 (C-thia-
diazole), 156.3, 128.7, 128.4, 125.7 (Ar), 81.7, 77.6, 76.9, 74.5,
70.0 (C-1 to C-5), 61.2 (C-6), 35.0 (Cq-tBu), 31.0 (CH3). Anal. Calcd
for C19H25N3O6S (423.48): C, 53.89, H, 5.95; N, 9.92; S, 7.57. Found:
C, 53.97; H, 6.02; N, 9.99; S, 7.50.
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